相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Severity-Adjusted Probability of Being Cost Effective
Matthijs M. Versteegh et al.
PHARMACOECONOMICS (2019)
A Contemporary View of Respiratory Syncytial Virus (RSV) Biology and Strain-Specific Differences
Mansi C. Pandya et al.
PATHOGENS (2019)
Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults
Bradley Ackerson et al.
CLINICAL INFECTIOUS DISEASES (2019)
Respiratory syncytial virus burden among adults during flu season: an underestimated pathology
M. Kestler et al.
JOURNAL OF HOSPITAL INFECTION (2018)
Respiratory Syncytial Virus Seasonality: A Global Overview
Pablo Obando-Pacheco et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Quality-adjusted Life Years (QALY) for 15 Chronic Conditions and Combinations of Conditions Among US Adults Aged 65 and Older
Haomiao Jia et al.
MEDICAL CARE (2018)
Measuring the cost of a pediatric vaccine administration in the UK
S. Mokiou et al.
VACCINE (2018)
A systematic review of economic evaluations of seasonal influenza vaccination for the elderly population in the European Union
Gemma E. Shields et al.
BMJ OPEN (2017)
Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK
Sylvia Taylor et al.
BMJ OPEN (2016)
Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom
Douglas M. Fleming et al.
BMC INFECTIOUS DISEASES (2015)
The burden of influenza in England by age and clinical risk group: A statistical analysis to inform vaccine policy
Deborah Cromer et al.
JOURNAL OF INFECTION (2014)
RSV vaccine in development: Assessing the potential cost-effectiveness in the Dutch elderly population
M. J. Meijboom et al.
VACCINE (2013)
Rates of Hospitalizations for Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza Virus in Older Adults
Kyle Widmer et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
The Impact of Pandemic Influenza H1N1 on Health-Related Quality of Life: A Prospective Population-Based Study
Albert Jan van Hoek et al.
PLOS ONE (2011)
Quantification of the Potential Impact of Cost-effectiveness Thresholds on Dutch Drug Expenditures Using Retrospective Analysis
Cornelis Boersma et al.
VALUE IN HEALTH (2010)
Factors that may impact on immunosenescence: an appraisal
Joseph Ongrádi et al.
Immunity & Ageing (2010)
Internet-based monitoring of influenza-like illness in the general population: Experience of five influenza seasons in the Netherlands
I. H. M. Friesema et al.
VACCINE (2009)
The NICE cost-effectiveness threshold - What it is and what that means
Christopher McCabe et al.
PHARMACOECONOMICS (2008)
The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly
BD Gessner
VACCINE (2000)